IBRX ▼ -0.2% - ImmunityBio, Inc.
$IBRX FDA WINS FIRST-EVER APPROVAL FOR ANKTIVA IN BCG-UNRESPONSIVE HIGH-GRADE PAPILLARY-ONLY BLADDER CANCER social media
14-OCT-2026 11:18 AM ET
Share this post
More filings for $IBRX
IBRX ▼ -0.2% - ImmunityBio, Inc.Oct 14, 2026IBRX ▼ -0.2% - ImmunityBio, Inc.Oct 14, 2026IBRX ▲ +5.1% - ImmunityBio, Inc.Oct 9, 2026IBRX ▼ -1.5% - ImmunityBio, Inc.Oct 8, 2026IBRX - ImmunityBio, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026
View full $IBRX filing history →💬 Comments
Loading comments…
Leave a comment